J&J's Janssen pharma group is chipping in $5 million for Stand Up To Cancer's health equity push in clinical trials. (Credit: Shutterstock)

J&J inks clin­i­cal tri­al deal with Stand Up To Can­cer, lat­est phar­ma to join can­cer non­prof­it study ef­forts

John­son & John­son’s new deal with a lead­ing can­cer or­ga­ni­za­tion aims to boost di­ver­si­ty in ear­ly phase clin­i­cal tri­als. The $5 mil­lion spon­sor­ship agree­ment be­tween Janssen and Stand Up To Can­cer (SU2C) will help fund four groups of re­searchers across the US work­ing to re­move bar­ri­ers to en­rolling more pa­tients, es­pe­cial­ly those in “med­ical­ly un­der­served” com­mu­ni­ties.

SU2C is cur­rent­ly tak­ing ap­pli­ca­tions for the re­search teams that will work with fed­er­al­ly qual­i­fied health cen­ters, clin­ics and lo­cal groups that are al­ready part­nered with the un­der­rep­re­sent­ed pop­u­la­tions. Team ap­pli­cants who get a sec­ond go-around and in­vi­ta­tion to sub­mit a full ap­pli­ca­tion will have un­til the end of Au­gust. Teams will be se­lect­ed in Sep­tem­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.